Europe
With revenue increase of 20 per cent in the first quarter we report all-time high net sales, first time over SEK 1.8 billion in a quarter.
Moderated posters feature clinical validations of SelectMDx and ConfirmMDx
In the study, tadalafil, the active ingredient in Cialis and Viagra, reversed the effects of heart failure, including the breathlessness associated with it.
The annual meeting of the American Society of Gene & Cell Therapy (ASGCT) was held in Washington, DC this week, with literally hundreds of abstracts and presentations. Here’s a look at some of the highlights.
The Management team of MorphoSys AG will host a conference call and webcast on May 8, 2019 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present MorphoSys’s first quarter interim statement 2019 and provide an outlook for 2019.
The treatment phase of the confirmatory phase III clinical study with gp-ASIT+™ in grass pollen rhinitis is now completed for all patients, in time before the grass pollen season, with no major safety concerns. DSMB recommends continuing the study without modification.
Tablet-Based Device Manager Provides Portable and Secure Wireless Programming of Medtronic BlueSync(TM) Devices
Direct integration of Genedata Bioprocess® and Umetrics® Suite MODDE® software enables seamless data flow and facilitates both design and execution of experiments in large-molecule process development
Finnish researchers at the University of Eastern Finland and the University of Oulu have discovered of a new type of gene mutation that reduces fear and anxiety, and increases social interaction.
Functional 2D and 3D in vitro assays using neuronal cells derived from iPSCs to assess the potential risk of TCR-mediated neurotoxicity
PRESS RELEASES